Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

  • Baxdela™(delafloxacin) Launched February 6, 2018, in U.S. for Adults with ABSSSI
  • Acquired Infectious Disease Business from The Medicines Company on January 5, 2018
  • First Earnings Report as a Public Company

Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided an update on commercial and regulatory activities for the quarter ended December 31, 2017. During the quarter, the Company completed its reverse merger with Cempra, Inc. (Cempra) to become a publicly traded company. Fourth quarter and full year 2017 results include the addition of the Cempra business as of the merger date of November 3, 2017. Immediately following the quarter, the Company acquired the infectious disease business of The Medicines Company, including products Vabomere™ (meropenem and vaborbactam), Orbactiv┬« (oritavancin) and Minocin┬« (minocycline) for Injection. This press release includes highlights from The Medicines Company infectious disease business as of acquisition close on January 5, 2018.

Read the full press releaseCompany website